Axol is a fresh and exciting biotech company providing highly validated, fully functional, clinically relevant iPS cell-derived neural progenitor cells and neurons from both healthy individuals and Alzheimer’s Disease patients.
Axol is providing researchers with an affordable, easily accessible, in vitro human system to complement their existing studies of cortical development, function and diseases, while helping them to avoid potential ethical challenges faced when considering the use of embryonic stem cells. The technology provides a platform for developing or testing novel therapeutic interventions and understanding the disease pathologies more thoroughly.
Come and see the Axol team at the AAIC 2014 in Copenhagen July 12-17 to find out more about them, their products and to discuss your research needs! Stand C1-107.
Read more: www.axolbio.com